About Us

Syed Kazmi is President and Chief Executive officer of Jubilant Therapeutics Inc., a subsidiary of Jubilant Pharmova Limited. Jubilant Therapeutics is a US-based innovative biopharmaceutical company developing breakthrough therapies for treating unmet medical needs in serious diseases such as cancer.

Previously, Syed worked as the Vice President and Global Head of Oncology Business Development & Licensing at Novartis, leading all BD&L efforts for Novartis Oncology including Search & Evaluation, Transactions, Due Diligence and Alliance Management. Prior to Novartis, Syed worked as the Executive Director of Business Development at Amgen, responsible for corporate mergers and acquisitions, global licensing and strategic collaborations; he also served as the Head of International Business Development.

Before joining Amgen in 2012, Syed served as Vice President and Head, Business Development & Strategic Planning, at Ligand Pharmaceuticals. Syed also worked for Johnson & Johnson as Principal Scientist in the R&D organization. Syed has a Ph.D. in Life Sciences (Biochemistry) and an executive MBA.

Shyam is CFO at Jubilant Therapeutics Inc. that he helped carve-out from the parent company Jubilant Pharmova Limited and set up as a standalone US-based biotech venture in 2019. Shyam is also involved in other initiatives at Jubilant such as corporate venture investing, digital and innovation.

Earlier he managed the strategy office at a leading India-based conglomerate where he helped scale a new business and managed a successful M&A exit valued at over a billion dollars. Before Shyam's industry stints, he spent most of his career as a management consultant at PwC – advising startups and leading global companies in strategy. Shyam has spoken at various conferences and is an active participant in the World Economic Forum community in addition to authoring over fifty thought leadership publications.

He is a graduate of the London School of Economics and State University of New York.

Ramachandraiah Gosu (Ram) is Director- Protein Chemistry of Jubilant Therapeutics Inc.. Ram brings wealth of experience in protein engineering, macromolecular X-ray Crystallography, Biophysics with special focus on small molecule drug discovery using SBDD and FBDD.

Previously he was heading Structural Biology department of Jubilant Biosys Ltd., Bangalore. He contributed in success of many challenging gene-to-structure projects of collaborators over 14 years and pioneered in establishing biophysical screening platform, SPR (Surface Plasmon Resonance).

Ram has published ~ 11 peer-reviewed journal articles and co-edited a book on "Methods for fragments screening using SPR", published by Springer Nature.

He holds Ph.D in Structural Biology from Molecular Biophysics Unit of Indian Institute of Science, Bangalore, India and gained post-doctoral experience at University of Minnesota, Minneapolis, USA.

Mohd Zainuddin is Director- Biology at Jubilant Therapeutics Inc. Previously, Zain worked on Drug metabolism and pharmacokinetics (DMPK) at Jubilant Biosys Ltd., where he has executed close to 40 Drug discovery projects from various pharma clients. He has in depth understanding on various domains of DMPK and has played a critical role in many successful lead and candidate nominations.

Zain has published nearly 45 peer-reviewed journal articles and holds 6 patents for inventorship in drug discovery and development.

He holds a Ph.D. in medical biochemistry from Aligarh Muslim University, Aligarh, India.

Agunan Krishnan is the Associate Director at Jubilant Therapeutics Inc., and with 14+ years of experience in the drug discovery field, is responsible for sales, marketing and business development. He is also responsible for establishing business partnerships and collaborations utilizing his expertise in the drug discovery process and techno-commercial knowledge.

Previously, Agunan worked at Jubilant Biosys, where he started as a research scientist in structural biology and transitioned into market research, strategy and business development. During his tenure he was involved in onboarding business opportunities and the out-licensing of a research program.

He has completed a bachelor’s degree in Veterinary Medicine from Madras Veterinary College, TANUVAS, India and post-graduate studies in Molecular Biology from Staffordshire University, UK.